Mexico City, Mexico
Mexico City, Mexico

Time filter

Source Type

Maffuz-Aziz A.,Institute Enfermedades Of La Mama | Labastida-Almendaro S.,Institute Enfermedades Of La Mama | Espejo-Fonseca A.,Institute Enfermedades Of La Mama | Rodriguez-Cuevas S.,Institute Enfermedades Of La Mama
Cirugia y Cirujanos (English Edition) | Year: 2016

Background: Breast cancer is the most common among women in our country, and its treatment is based on prognostic factors to categorize patients into different risk groups. In this study, the clinical and pathological features that play a role as a prognostic factor in a representative population with breast cancer in México are described. Material and methods: A descriptive analysis of the clinical and pathological features of women diagnosed with breast cancer, in a period from June 2005 to May 2014; registered in a database and calculated by simple frequencies. Results: A total of 4,411 patients were included, the average age at diagnosis was 53 years, 19.7% were diagnosed by mammography screening program and 80.3% derived from any signs or symptoms. Regarding the stages at diagnosis, 6.8% were carcinoma in situ, 36% at early stages (I and IIA), 45% locally advanced (IIB to IIIC), 7.7% metastatic and 3.9% unclassifiable. A 79% were ductal histology, lobular 7.8% and the rest, other types. Of ductal carcinomas, 9.1% were grade I, 54.1% grade II, and 34.6% grade III. Regarding the biological subtypes, 65.7% were luminal, 10.9% luminal Her positive, 8.7% pure Her 2 positive and 14.6% triple negative. Conclusion: In the present study, we described the clinical and pathologic features of a group of Mexican women with breast cancer that might reflect a national landscape, and represent the prognostic factors to determine groups of risk and treatment decisions. © 2016 Academia Mexicana de Cirugía A.C.


Calderon-Gonzalez K.G.,Metropolitan Autonomous University | Valero Rustarazo M.L.,Research Center Principe Felipe | Valero Rustarazo M.L.,University of Valencia | Labra-Barrios M.L.,National Polytechnic Institute of Mexico | And 12 more authors.
Journal of Proteomics | Year: 2015

Breast cancer is the principal cancer in women worldwide. Although there are serum tumor markers such as CEA and HER2, they are detected in advanced stages of the disease and used as progression and recurrence markers. Therefore, there is a necessity for the identification of new markers that might lead to an early detection and also provide evidence of an effective treatment. The aim of this work was to determine the differential protein expression profiles of four breast cancer cell lines in comparison to a normal control cell line by iTRAQ labelling and tandem mass spectrometry, in order to identify putative biomarkers of the disease. We identified 1,020 iTRAQ-labelled polypeptides with at least one peptide identified with more than 95% in confidence. Overexpressed polypeptides in all cancer cell lines were 78, whilst the subexpressed were 128. We categorised them with PANTHER program into biological processes, being the metabolic pathways the most affected. We detected six groups of proteins with the STRING program involved in DNA topology, glycolysis, translation initiation, splicing, pentose pathway, and proteasome degradation. The main subexpressed protein network included mitochondrial proteins involved in oxidative phosphorylation. We propose BAG6, DDX39, ANXA8 and COX4 as putative biomarkers in breast cancer. Biological significance: We report a set of differentially expressed proteins in the MCF7 and T47D (Luminal A), MDA-MB-231 (Claudin low) and SK-BR-3 (HER2+) breast cancer cell lines that have not been previously reported in breast cancer disease. From these proteins, we propose BAG6, DDX39, ANXA8 and COX4 as putative biomarkers in breast cancer. On the other hand, we propose sets of unique polypeptides in each breast cancer cell line that can be useful in the classification of different subtypes of breast cancer. © 2015 Elsevier B.V.


Medina-Aguilar R.,CINVESTAV | Perez-Plasencia C.,National Autonomous University of Mexico | Marchat L.A.,National Polytechnic Institute of Mexico | Gariglio P.,CINVESTAV | And 7 more authors.
PLoS ONE | Year: 2016

Aberrant DNA methylation is a frequent epigenetic alteration in cancer cells that has emerged as a pivotal mechanism for tumorigenesis. Accordingly, novel therapies targeting the epigenome are being explored with the aim to restore normal DNA methylation patterns on oncogenes and tumor suppressor genes. A limited number of studies indicate that dietary compound resveratrol modulates DNA methylation of several cancer-related genes; however a complete view of changes in methylome by resveratrol has not been reported yet. In this study we performed a genome-wide survey of DNA methylation signatures in triple negative breast cancer cells exposed to resveratrol. Our data showed that resveratrol treatment for 24 h and 48 h decreased gene promoter hypermethylation and increased DNA hypomethylation. Of 2476 hypermethylated genes in control cells, 1,459 and 1,547 were differentially hypomethylated after 24 h and 48 h, respectively. Remarkably, resveratrol did not induce widespread non-specific DNA hyper- or hypomethylation as changes in methylation were found in only 12.5% of 27,728 CpG loci. Moreover, resveratrol restores the hypomethylated and hypermethylated status of key tumor suppressor genes and oncogenes, respectively. Importantly, the integrative analysis of methylome and transcriptome profiles in response to resveratrol showed that methylation alterations were concordant with changes in mRNA expression. Our findings reveal for the first time the impact of resveratrol on the methylome of breast cancer cells and identify novel potential targets for epigenetic therapy. We propose that resveratrol may be considered as a dietary epidrug as it may exert its anti-tumor activities by modifying the methylation status of cancer -related genes which deserves further in vivo characterization. © 2016 Medina-Aguilar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


PubMed | Research Center Principe Felipe, Institute Enfermedades Of La Mama, National Polytechnic Institute of Mexico, Metropolitan Autonomous University and AB SCIEX
Type: | Journal: Data in brief | Year: 2015

Breast cancer is the most common and the leading cause of mortality in women worldwide. There is a dire necessity of the identification of novel molecules useful in diagnosis and prognosis. In this work we determined the differentially expression profiles of four breast cancer cell lines compared to a control cell line. We identified 1020 polypeptides labelled with iTRAQ with more than 95% in confidence. We analysed the common proteins in all breast cancer cell lines through IPA software (IPA core and Biomarkers). In addition, we selected the specific overexpressed and subexpressed proteins of the different molecular classes of breast cancer cell lines, and classified them according to protein class and biological process. Data in this article is related to the research article Determination of the protein expression profiles of breast cancer cell lines by Quantitative Proteomics using iTRAQ Labelling and Tandem Mass Spectrometry (Caldern-Gonzlez et al. [1] in press).


PubMed | Research Center Principe Felipe, Institute Enfermedades Of La Mama, National Polytechnic Institute of Mexico, Metropolitan Autonomous University and AB SCIEX
Type: | Journal: Journal of proteomics | Year: 2015

Breast cancer is the principal cancer in women worldwide. Although there are serum tumor markers such as CEA and HER2, they are detected in advanced stages of the disease and used as progression and recurrence markers. Therefore, there is a necessity for the identification of new markers that might lead to an early detection and also provide evidence of an effective treatment. The aim of this work was to determine the differential protein expression profiles of four breast cancer cell lines in comparison to a normal control cell line by iTRAQ labelling and tandem mass spectrometry, in order to identify putative biomarkers of the disease. We identified 1,020 iTRAQ-labelled polypeptides with at least one peptide identified with more than 95% in confidence. Overexpressed polypeptides in all cancer cell lines were 78, whilst the subexpressed were 128. We categorised them with PANTHER program into biological processes, being the metabolic pathways the most affected. We detected six groups of proteins with the STRING program involved in DNA topology, glycolysis, translation initiation, splicing, pentose pathway, and proteasome degradation. The main subexpressed protein network included mitochondrial proteins involved in oxidative phosphorylation. We propose BAG6, DDX39, ANXA8 and COX4 as putative biomarkers in breast cancer.We report a set of differentially expressed proteins in the MCF7 and T47D (Luminal A), MDA-MB-231 (Claudin low) and SK-BR-3 (HER2(+)) breast cancer cell lines that have not been previously reported in breast cancer disease. From these proteins, we propose BAG6, DDX39, ANXA8 and COX4 as putative biomarkers in breast cancer. On the other hand, we propose sets of unique polypeptides in each breast cancer cell line that can be useful in the classification of different subtypes of breast cancer.


Mariana V.C.,National Autonomous University of Mexico | Cesar R.T.,National Autonomous University of Mexico | Ruby E.F.,Institute Enfermedades Of La Mama
AIP Conference Proceedings | Year: 2014

Mammography is the best tool for early detection of Breast Cancer. In this diagnostic radiology modality it is necessary to establish the criteria to ensure the proper use and operation of the equipment used to obtain mammographic images in order to contribute to the safe use of ionizing radiation. The aim of the work was to implement at FUCAM-AC the radiation protection program which must be established for patients and radiation workers according to Mexican standards [1-4]. To achieve this goal, radiation protection and quality control manuals were elaborated [5]. Furthermore, a quality control program (QCP) in the mammography systems (analog/digital), darkroom included, has been implemented. Daily sensitometry, non-variability of the image quality, visualizing artifacts, revision of the equipment mechanical stability, compression force and analysis of repetition studies are some of the QCP routine tests that must be performed by radiological technicians of this institution as a set of actions to ensure the protection of patients. Image quality and patients dose assessment were performed on 4 analog equipment installed in 2 mobile units. In relation to dose assessment, all equipment passed the acceptance criteria (<3 mGy per projection). The image quality test showed that most images (70%)-presented artifacts. A brief summary of the results of quality control tests applied to the equipment and film processor are presented. To maintain an adequate level of quality and safety at FUCAM-AC is necessary that the proposed radiation protection program in this work is applied. © 2014 AIP Publishing LLC.


Tizatl A.L.V.,CINVESTAV | Cuevas S.R.,Institute Enfermedades Of La Mama | Salas L.L.,CINVESTAV | Hernandez A.V.,CINVESTAV
2016 Global Medical Engineering Physics Exchanges/Pan American Health Care Exchanges, GMEPE/PAHCE 2016 | Year: 2016

Electrochemotherapy is an electroporationbased treatment successfully used in palliation of cutaneous and subcutaneous tumors. Its high response rate encourage further research on electrochemotherapy applied in deep tissues as a minimally invasive procedure for primary tumors. In order to assess electrochemotherapy effectiveness in breast primary tumors in Mexico, it is presented a review of background, current aspects and perspectives of this technique reported in Europe thus the identification of technological requirements to be attended are discussed. © 2016 IEEE.


Sherwell-Cabello S.,Institute Enfermedades Of La Mama | Maffuz-Aziz A.,Institute Enfermedades Of La Mama | Villegas-Carlos F.,Institute Enfermedades Of La Mama | Dominguez-Reyes C.,Institute Enfermedades Of La Mama | And 2 more authors.
Cirugia y Cirujanos | Year: 2015

Background: Breast cancer is the leading oncological cause of death in Mexican women over25 years old. Given the need to improve postoperative cosmetic results in patients with breastcancer, oncoplastic surgery has been developed, which allows larger tumour resections andminor cosmetic alterations.Objective: To determine the oncological feasibility and cosmetic outcome of oncoplastic sur-gery at the Instituto de Enfermedades de la Mama, FUCAM, AC.Material and methods:A review was conducted from January 2010 to July 2013, which includedpatients with breast cancer diagnosis treated with conventional breast-conserving surgery orwith oncoplastic surgery in the Institute of Diseases of the Breast, FUCAM AC. Clinical andhistopathological parameters were compared between the two groups, and a questionnaire ofcosmetic satisfaction and quality of life was applied.Results: Of the 171 patients included, 95 of them were treated with conventional breast-conserving surgery and 76 with oncoplastic surgery. Pathological tumour size was significantlylarger in patients treated with oncoplastic surgery (p = 0.002). There were no differences foundbetween the groups as regards the number of patients with positive surgical margin, the rateof complications, and cosmetic satisfaction.Conclusion: This study demonstrates the oncological feasibility and high cosmetic satisfactionof oncoplastic surgery with minimal psycho-social impact on patients. © 2015 Academia Mexicana de Cirugia A.C. Publicado por Masson Doyma México S.A.


PubMed | Institute Enfermedades Of La Mama
Type: | Journal: Cirugia y cirujanos | Year: 2016

Breast cancer is the most common among women in our country, and its treatment is based on prognostic factors to categorize patients into different risk groups. In this study, the clinical and pathological features that play a role as a prognostic factor in a representative population with breast cancer in Mxico are described.A descriptive analysis of the clinical and pathological features of women diagnosed with breast cancer, in a period from June 2005 to May 2014; registered in a database and calculated by simple frequencies.A total of 4,411 patients were included, the average age at diagnosis was 53 years, 19.7% were diagnosed by mammography screening program and 80.3% derived from any signs or symptoms. Regarding the stages at diagnosis, 6.8% were carcinoma in situ, 36% at early stages (I and IIA), 45% locally advanced (IIB to IIIC), 7.7% metastatic and 3.9% unclassifiable. A 79% were ductal histology, lobular 7.8% and the rest, other types. Of ductal carcinomas, 9.1% were grade I, 54.1% grade II, and 34.6% grade III. Regarding the biological subtypes, 65.7% were luminal, 10.9% luminal Her positive, 8.7% pure Her 2 positive and 14.6% triple negative.In the present study, we described the clinical and pathologic features of a group of Mexican women with breast cancer that might reflect a national landscape, and represent the prognostic factors to determine groups of risk and treatment decisions.


PubMed | Institute Enfermedades Of La Mama
Type: Journal Article | Journal: Cirugia y cirujanos | Year: 2015

Breast cancer is the leading oncological cause of death in Mexican women over 25 years old. Given the need to improve postoperative cosmetic results in patients with breast cancer, oncoplastic surgery has been developed, which allows larger tumour resections and minor cosmetic alterations.To determine the oncological feasibility and cosmetic outcome of oncoplastic surgery at the Instituto de Enfermedades de la Mama, FUCAM, AC.A review was conducted from January 2010 to July 2013, which included patients with breast cancer diagnosis treated with conventional breast-conserving surgery or with oncoplastic surgery in the Institute of Diseases of the Breast, FUCAM AC. Clinical and histopathological parameters were compared between the two groups, and a questionnaire of cosmetic satisfaction and quality of life was applied.Of the 171 patients included, 95 of them were treated with conventional breast-conserving surgery and 76 with oncoplastic surgery. Pathological tumour size was significantly larger in patients treated with oncoplastic surgery (p = 0.002). There were no differences found between the groups as regards the number of patients with positive surgical margin, the rate of complications, and cosmetic satisfaction.This study demonstrates the oncological feasibility and high cosmetic satisfaction of oncoplastic surgery with minimal psycho-social impact on patients.

Loading Institute Enfermedades Of La Mama collaborators
Loading Institute Enfermedades Of La Mama collaborators